The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Related to this article
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
Advertisement
Advertisement
Trending on Dermatology Times
1
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
2
Social Media Mythbusters: At-Home Dermarollers
3
ORKA-001 Achieves Deepening Skin Clearance Through Week 28 in Plaque Psoriasis
4
Barzolvolimab Achieves All Phase 3 End Points in Chronic Spontaneous Urticaria
5